Racial Disparities in Infliximab Efficacy for Ulcerative Colitis: Evidence Synthesis and Effect Modification Assessment
Abstract
:1. Introduction
2. Materials and Methods
2.1. Data Sources
2.2. Quality Assessment
2.3. Racial Categories
2.4. Outcomes Assessed
2.5. Statistical Methods
3. Results
3.1. Quality Assessment
3.2. Assessment of Racial Differences in Treatment Efficacy of IFX
3.2.1. Induction of Clinical Response
3.2.2. Induction of Clinical Remission
3.2.3. Induction of Mucosal Healing
3.2.4. Maintenance of Clinical Remission
3.2.5. Maintenance of Mucosal Healing
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Le Berre, C.; Honap, S.; Peyrin-Biroulet, L. Ulcerative colitis. Lancet 2023, 402, 571–584. [Google Scholar] [CrossRef] [PubMed]
- Danese, S.; Fiocchi, C. Ulcerative colitis. N. Engl. J. Med. 2011, 365, 1713–1725. [Google Scholar] [CrossRef] [PubMed]
- Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.Y.; Chan, F.K.L.; et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2018, 390, 2769–2778. [Google Scholar] [CrossRef] [PubMed]
- Piovani, D.; Danese, S.; Peyrin-Biroulet, L.; Bonovas, S. Inflammatory bowel disease: Estimates from the global burden of disease 2017 study. Aliment. Pharmacol. Ther. 2020, 51, 261–270. [Google Scholar] [CrossRef]
- de Lange, K.M.; Moutsianas, L.; Lee, J.C.; Lamb, C.A.; Luo, Y.; Kennedy, N.A.; Jostins, L.; Rice, D.L.; Gutierrez-Achury, J.; Ji, S.G.; et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat. Genet. 2017, 49, 256–261. [Google Scholar] [CrossRef]
- Piovani, D.; Danese, S.; Peyrin-Biroulet, L.; Nikolopoulos, G.K.; Lytras, T.; Bonovas, S. Environmental risk factors for inflammatory bowel diseases: An umbrella review of meta-analyses. Gastroenterology 2019, 157, 647–659. [Google Scholar] [CrossRef]
- Piovani, D.; Pansieri, C.; Kotha, S.R.R.; Piazza, A.C.; Comberg, C.L.; Peyrin-Biroulet, L.; Danese, S.; Bonovas, S. Ethnic differences in the smoking-related risk of inflammatory bowel disease: A systematic review and meta-analysis. J. Crohns Colitis 2021, 15, 1658–1678. [Google Scholar] [CrossRef]
- Cohen, R.D.; Yu, A.P.; Wu, E.Q.; Xie, J.; Mulani, P.M.; Chao, J. Systematic review: The costs of ulcerative colitis in Western countries. Aliment. Pharmacol. Ther. 2010, 31, 693–707. [Google Scholar] [CrossRef]
- Paschos, P.; Katsoula, A.; Salanti, G.; Giouleme, O.; Athanasiadou, E.; Tsapas, A. Systematic review with network meta-analysis: The impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. Aliment. Pharmacol. Ther. 2018, 48, 1174–1185. [Google Scholar] [CrossRef]
- Feuerstein, J.D.; Isaacs, K.L.; Schneider, Y.; Siddique, S.M.; Falck-Ytter, Y.; Singh, S.; AGA Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology 2020, 158, 1450–1461. [Google Scholar] [CrossRef]
- Singh, S.; Allegretti, J.R.; Siddique, S.M.; Terdiman, J.P. AGA technical review on the management of moderate to severe ulcerative colitis. Gastroenterology 2020, 158, 1465–1496.e17. [Google Scholar] [CrossRef] [PubMed]
- Macaluso, F.S.; Orlando, A.; Papi, C.; Festa, S.; Pugliese, D.; Bonovas, S.; Pansieri, C.; Piovani, D.; Fiorino, G.; Fantini, M.C.; et al. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Dig. Liver Dis. 2022, 54, 440–451. [Google Scholar] [CrossRef]
- Pantavou, K.; Yiallourou, A.I.; Piovani, D.; Evripidou, D.; Danese, S.; Peyrin-Biroulet, L.; Bonovas, S.; Nikolopoulos, G.K. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. United Eur. Gastroenterol. J. 2019, 7, 1285–1303. [Google Scholar] [CrossRef] [PubMed]
- Bonovas, S.; Lytras, T.; Nikolopoulos, G.; Peyrin-Biroulet, L.; Danese, S. Systematic review with network meta-analysis: Comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment. Pharmacol. Ther. 2018, 47, 454–465. [Google Scholar] [CrossRef] [PubMed]
- Rutgeerts, P.; Vermeire, S.; Van Assche, G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009, 136, 1182–1197. [Google Scholar] [CrossRef] [PubMed]
- Rutgeerts, P.; Van Assche, G.; Vermeire, S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004, 126, 1593–1610. [Google Scholar] [CrossRef] [PubMed]
- Cornillie, F.; Shealy, D.; D’Haens, G.; Geboes, K.; Van Assche, G.; Ceuppens, J.; Wagner, C.; Schaible, T.; Plevy, S.; Targan, S.R.; et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment. Pharmacol. Ther. 2001, 15, 463–473. [Google Scholar] [CrossRef]
- Danese, S.; Fiorino, G.; Peyrin-Biroulet, L.; Lucenteforte, E.; Virgili, G.; Moja, L.; Bonovas, S. Biological agents for moderately to severely active ulcerative colitis: A systematic review and network meta-analysis. Ann. Intern. Med. 2014, 160, 704–711. [Google Scholar] [CrossRef]
- Nguyen, G.C.; LaVeist, T.A.; Harris, M.L.; Wang, M.H.; Datta, L.W.; Brant, S.R. Racial disparities in utilization of specialist care and medications in inflammatory bowel disease. Am. J. Gastroenterol. 2010, 105, 2202–2208. [Google Scholar] [CrossRef]
- Flasar, M.H.; Quezada, S.; Bijpuria, P.; Cross, R.K. Racial differences in disease extent and severity in patients with ulcerative colitis: A retrospective cohort study. Dig. Dis. Sci. 2008, 53, 2754–2760. [Google Scholar] [CrossRef]
- Moore, L.; Gaffney, K.; Lopez, R.; Shen, B. Comparison of the natural history of ulcerative colitis in African Americans and non-Hispanic Caucasians: A historical cohort study. Inflamm. Bowel. Dis. 2012, 18, 743–749. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, G.C.; Torres, E.A.; Regueiro, M.; Bromfield, G.; Bitton, A.; Stempak, J.; Dassopoulos, T.; Schumm, P.; Gregory, F.J.; Griffiths, A.M.; et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: Characterization of a large North American cohort. Am. J. Gastroenterol. 2006, 101, 1012–1023. [Google Scholar] [CrossRef] [PubMed]
- Damas, O.M.; Jahann, D.A.; Reznik, R.; McCauley, J.L.; Tamariz, L.; Deshpande, A.R.; Abreu, M.T.; Sussman, D.A. Phenotypic manifestations of inflammatory bowel disease differ between Hispanics and non-Hispanic whites: Results of a large cohort study. Am. J. Gastroenterol. 2013, 108, 231–239. [Google Scholar] [CrossRef] [PubMed]
- Lian, L.; Moore, L.; Wu, X.J.; He, X.S.; Lan, P.; Shen, B. Different clinical characteristics in Hispanic and non-Hispanic whites with ileal pouch-anal anastomosis: A case-control study. Inflamm. Bowel. Dis. 2011, 17, 1003–1007. [Google Scholar] [CrossRef]
- Hou, J.; El-Serag, H.; Sellin, J.; Thirumurthi, S. Inflammatory bowel disease characteristics and treatment in Hispanics and Caucasians. Dig. Dis. Sci. 2011, 56, 1476–1481. [Google Scholar] [CrossRef] [PubMed]
- Hou, J.K.; El-Serag, H.; Thirumurthi, S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: A systematic review. Am. J. Gastroenterol. 2009, 104, 2100–2109. [Google Scholar] [CrossRef]
- Shi, H.Y.; Levy, A.N.; Trivedi, H.D.; Chan, F.K.L.; Ng, S.C.; Ananthakrishnan, A.N. Ethnicity influences phenotype and outcomes in inflammatory bowel disease: A systematic review and meta-analysis of population-based studies. Clin. Gastroenterol. Hepatol. 2018, 16, 190–197.e11. [Google Scholar] [CrossRef]
- Simsek, H.; Schuman, B.M. Inflammatory bowel disease in 64 black patients: Analysis of course, complications, and surgery. J. Clin. Gastroenterol. 1989, 11, 294–298. [Google Scholar] [CrossRef]
- Borrell, L.N.; Elhawary, J.R.; Fuentes-Afflick, E.; Witonsky, J.; Bhakta, N.; Wu, A.H.B.; Bibbins-Domingo, K.; Rodríguez-Santana, J.R.; Lenoir, M.A.; Gavin, J.R., 3rd; et al. Race and genetic ancestry in medicine—A time for reckoning with racism. N. Engl. J. Med. 2021, 384, 474–480. [Google Scholar] [CrossRef]
- Greywoode, R.; Petralia, F.; Ullman, T.A.; Frederic Colombel, J.; Ungaro, R.C. Racial difference in efficacy of golimumab in ulcerative colitis. Inflamm. Bowel Dis. 2023, 29, 843–849. [Google Scholar] [CrossRef]
- Bonovas, S.; Pansieri, C.; Piovani, D.; Macaluso, F.S.; Orlando, A.; Festa, S.; Papi, C.; Pugliese, D.; Armuzzi, A. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology. Dig. Liver Dis. 2022, 54, 428–439. [Google Scholar] [CrossRef] [PubMed]
- Higgins, J.P.; Altman, D.G.; Gøtzsche, P.C.; Jüni, P.; Moher, D.; Oxman, A.D.; Savovic, J.; Schulz, K.F.; Weeks, L.; Sterne, J.A. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011, 343, d5928. [Google Scholar] [CrossRef] [PubMed]
- Schroeder, K.W.; Tremaine, W.J.; Ilstrup, D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomised study. N. Engl. J. Med. 1987, 317, 1625–1629. [Google Scholar] [CrossRef] [PubMed]
- Mantel, N.; Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22, 719–748. [Google Scholar]
- Harville, D.A. Maximum likelihood approaches to variance component estimation and to related problems. J. Am. Stat. Assoc. 1977, 72, 320–338. [Google Scholar] [CrossRef]
- Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557–560. [Google Scholar] [CrossRef]
- Sterne, J.A.; Sutton, A.J.; Ioannidis, J.P.; Terrin, N.; Jones, D.R.; Lau, J.; Carpenter, J.; Rücker, G.; Harbord, R.M.; Schmid, C.H.; et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011, 343, d4002. [Google Scholar] [CrossRef]
- Altman, D.G.; Bland, J.M. Interaction revisited: The difference between two estimates. BMJ 2003, 326, 219. [Google Scholar] [CrossRef]
- R Development Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing; R Development Core Team: Vienna, Austria, 2014. [Google Scholar]
- Jiang, X.L.; Cui, H.F.; Gao, J.; Fan, H. Low-dose infliximab for induction and maintenance treatment in Chinese patients with moderate to severe active ulcerative colitis. J. Clin. Gastroenterol. 2015, 49, 582–588. [Google Scholar] [CrossRef]
- ClinicalTrials.gov, Xi’an Janssen. 2015. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Infliximab in Chinese Subjects with Active Ulcerative Colitis. Available online: https://clinicaltrials.gov/study/NCT01551290 (accessed on 17 November 2023).
- Kobayashi, T.; Suzuki, Y.; Motoya, S.; Hirai, F.; Ogata, H.; Ito, H.; Sato, N.; Ozaki, K.; Watanabe, M.; Hibi, T. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis. J. Gastroenterol. 2016, 51, 241–251. [Google Scholar] [CrossRef]
- Rutgeerts, P.; Sandborn, W.J.; Feagan, B.G.; Reinisch, W.; Olson, A.; Johanns, J.; Travers, S.; Rachmilewitz, D.; Hanauer, S.B.; Lichtenstein, G.R.; et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2005, 353, 2462–2476. [Google Scholar] [CrossRef] [PubMed]
- Sandborn, W.J.; Feagan, B.G.; Marano, C.; Zhang, H.; Strauss, R.; Johanns, J.; Adedokun, O.J.; Guzzo, C.; Colombel, J.F.; Reinisch, W.; et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014, 146, 85–95. [Google Scholar] [CrossRef] [PubMed]
- Sandborn, W.J.; Feagan, B.G.; Marano, C.; Zhang, H.; Strauss, R.; Johanns, J.; Adedokun, O.J.; Guzzo, C.; Colombel, J.F.; Reinisch, W.; et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014, 146, 96–109.e1. [Google Scholar] [CrossRef] [PubMed]
- Hibi, T.; Imai, Y.; Senoo, A.; Ohta, K.; Ukyo, Y. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: A phase 3, double-blind, randomized, placebo-controlled study (PURSUIT-J study). J. Gastroenterol. 2017, 52, 1101–1111. [Google Scholar] [CrossRef] [PubMed]
- Osborne, N.G.; Feit, M.D. The use of race in medical research. JAMA 1992, 267, 275–279. [Google Scholar] [CrossRef] [PubMed]
- Schwartz, R.S. Racial profiling in medical research. N. Engl. J. Med. 2001, 344, 1392–1393. [Google Scholar] [CrossRef] [PubMed]
- Satel, S.L. PC, MD: How Political Correctness Is Corrupting Medicine; Basic Books: New York, NY, USA, 2000. [Google Scholar]
- Owens, K.; King, M.C. Genomic views of human history. Science 1999, 286, 451–453. [Google Scholar] [CrossRef]
- Hahn, R.A. The state of federal health statistics on racial and ethnic groups. JAMA 1992, 267, 268–271. [Google Scholar] [CrossRef]
- American Medical Association. New AMA Policies Recognize Race as a Social, Not Biological, Construct. 16 November 2020. Available online: https://www.ama-assn.org/press-center/press-releases/new-ama-policies-recognize-race-social-not-biological-construct (accessed on 17 November 2023).
- Sherin, K.; Adebanjo, T.; Jani, A. Social determinants of health: Family physicians’ leadership role. Am. Fam. Physician 2019, 99, 476–477. [Google Scholar]
- Schandelmaier, S.; Briel, M.; Varadhan, R.; Schmid, C.H.; Devasenapathy, N.; Hayward, R.A.; Gagnier, J.; Borenstein, M.; van der Heijden, G.J.M.G.; Dahabreh, I.J.; et al. Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ 2020, 192, E901–E906. [Google Scholar] [CrossRef]
- Borenstein, M.; Higgins, J.P. Meta-analysis and subgroups. Prev. Sci. 2013, 14, 134–143. [Google Scholar] [CrossRef] [PubMed]
- Altman, D.G.; Bland, J.M. Absence of evidence is not evidence of absence. BMJ 1995, 311, 485. [Google Scholar] [CrossRef] [PubMed]
- Cuijpers, P.; Griffin, J.W.; Furukawa, T.A. The lack of statistical power of subgroup analyses in meta-analyses: A cautionary note. Epidemiol. Psychiatr. Sci. 2021, 30, e78. [Google Scholar] [CrossRef] [PubMed]
- Murthy, V.H.; Krumholz, H.M.; Gross, C.P. Participation in cancer clinical trials: Race-, sex-, and age-based disparities. JAMA 2004, 291, 2720–2726. [Google Scholar] [CrossRef]
- Sardar, M.R.; Badri, M.; Prince, C.T.; Seltzer, J.; Kowey, P.R. Under-representation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. JAMA Intern. Med. 2014, 174, 1868–1870. [Google Scholar] [CrossRef]
- Oh, S.S.; Galanter, J.; Thakur, N.; Pino-Yanes, M.; Barcelo, N.E.; White, M.J.; de Bruin, D.M.; Greenblatt, R.M.; Bibbins-Domingo, K.; Wu, A.H.; et al. Diversity in clinical and biomedical research: A promise yet to be fulfilled. PLoS Med. 2015, 12, e1001918. [Google Scholar] [CrossRef]
Study; Population Race | Acronym; ClinicalTrials.gov ID | Study Groups, Intervention Parameters, Number of Patients | Follow-Up |
---|---|---|---|
Jiang et al., 2015 [40]; Chinese, 100% of patients | IFX (5 mg/kg IV at wks 0, 2, 6, and q8w thereafter) (n = 41) vs. PBO (n = 41) | 30 wks | |
Xi’an Janssen, 2015 [41]; Chinese, 100% of patients | NCT01551290 | IFX (5 mg/kg IV at wks 0, 2, 6, and q8w thereafter) (n = 50) vs. PBO (n = 49) | 26 wks |
Kobayashi et al., 2016 [42]; Japanese, 100% of patients | Japic CTI-060298 | IFX (5 mg/kg IV at wks 0, 2, 6, and q8w thereafter) (n = 104) vs. PBO (n = 104) | 30 wks |
Rutgeerts et al., 2005 [43]; Caucasians, 94% of patients | ACT 1; NCT00036439 | IFX (5 mg/kg IV at wks 0, 2, 6, and q8w thereafter) (n = 121) vs. PBO (n = 121) | 54 wks |
Rutgeerts et al., 2005 [43]; Caucasians, 95% of patients | ACT 2; NCT00096655 | IFX (5 mg/kg IV at wks 0, 2, 6, and q8w thereafter) (n = 121) vs. PBO (n = 123) | 30 wks |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bonovas, S.; Tsantes, A.G.; Sokou, R.; Tsantes, A.E.; Nikolopoulos, G.K.; Piovani, D. Racial Disparities in Infliximab Efficacy for Ulcerative Colitis: Evidence Synthesis and Effect Modification Assessment. J. Clin. Med. 2024, 13, 319. https://doi.org/10.3390/jcm13020319
Bonovas S, Tsantes AG, Sokou R, Tsantes AE, Nikolopoulos GK, Piovani D. Racial Disparities in Infliximab Efficacy for Ulcerative Colitis: Evidence Synthesis and Effect Modification Assessment. Journal of Clinical Medicine. 2024; 13(2):319. https://doi.org/10.3390/jcm13020319
Chicago/Turabian StyleBonovas, Stefanos, Andreas G. Tsantes, Rozeta Sokou, Argirios E. Tsantes, Georgios K. Nikolopoulos, and Daniele Piovani. 2024. "Racial Disparities in Infliximab Efficacy for Ulcerative Colitis: Evidence Synthesis and Effect Modification Assessment" Journal of Clinical Medicine 13, no. 2: 319. https://doi.org/10.3390/jcm13020319
APA StyleBonovas, S., Tsantes, A. G., Sokou, R., Tsantes, A. E., Nikolopoulos, G. K., & Piovani, D. (2024). Racial Disparities in Infliximab Efficacy for Ulcerative Colitis: Evidence Synthesis and Effect Modification Assessment. Journal of Clinical Medicine, 13(2), 319. https://doi.org/10.3390/jcm13020319